What is the success rate of immunotherapy in cancer patients?

Immunotherapy has shown promising results in multiple clinical trials and real-world studies across various types of cancer. One of the most impressive immunotherapies is CAR T-cell therapy, which boasts a 90% overall response rate among patients with advanced B-cell non—Hodgkin lymphoma, according to research published this year in The New England Journal of Medicine. However, other treatments such as checkpoint inhibitors have had varying rates of success depending on the type of cancer being treated. For example, melanoma treated with PD-1 blockers have reported response rates from 20 to 60%, and treatment for Hodgkin's lymphoma may reach up to 80%.

Overall, immunotherapy is becoming a powerful tool in treating many different kinds of cancer and offers hope for those diagnosed with the disease. As researchers continue pushing forward into the field, we may see even higher success rates in the future.